Wedbush Predicts AnaptysBio’s Q1 Earnings (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB) – Equities research analysts at Wedbush lifted their Q1 2025 earnings estimates for AnaptysBio in a research note issued on Monday, February 3rd. Wedbush analyst D. Nierengarten now expects that the biotechnology company will earn ($0.44) per share for the quarter, up from their previous estimate of ($0.96). Wedbush currently has a “Outperform” rating and a $40.00 price target on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. Wedbush also issued estimates for AnaptysBio’s Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.05) EPS, FY2026 earnings at ($3.75) EPS, FY2027 earnings at ($4.13) EPS and FY2028 earnings at ($4.77) EPS.

A number of other research analysts also recently commented on ANAB. Truist Financial dropped their price objective on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. HC Wainwright reaffirmed a “neutral” rating and set a $19.00 price target on shares of AnaptysBio in a research note on Tuesday. UBS Group lifted their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. dropped their price objective on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a report on Thursday, December 19th. Finally, Wells Fargo & Company reduced their target price on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, December 12th. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $40.08.

AnaptysBio Trading Down 2.7 %

AnaptysBio stock opened at $16.06 on Wednesday. The stock has a fifty day moving average price of $17.05 and a 200 day moving average price of $26.77. AnaptysBio has a 52 week low of $12.51 and a 52 week high of $41.31. The firm has a market capitalization of $488.71 million and a P/E ratio of -2.64.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%.

Insiders Place Their Bets

In other news, Director Ecor1 Capital, Llc acquired 6,646 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was bought at an average cost of $12.95 per share, with a total value of $86,065.70. Following the transaction, the director now directly owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. This represents a 0.08 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 33.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Values First Advisors Inc. acquired a new stake in AnaptysBio in the third quarter valued at $49,000. nVerses Capital LLC lifted its holdings in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 1,400 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in AnaptysBio by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 644 shares during the period. Point72 DIFC Ltd grew its position in AnaptysBio by 680.5% in the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock worth $205,000 after purchasing an additional 5,342 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in AnaptysBio by 35.0% in the 4th quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company’s stock worth $216,000 after buying an additional 4,231 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.